LEGN

Business Context and Reporting Period

Company: Legend Biotech Corporation (LEGN)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Legend Biotech is a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of novel cell therapies, primarily CAR-T therapies. Its lead product, CARVYKTI (cilta-cel), is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). The company operates through subsidiaries in the United States, China, and the European Union.

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The company reported a significant unrealized foreign exchange gain of $108.5 million in 2024, which reduced the reported net loss compared to 2023.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 119.9% to $627.2 million, driven by a 93.1% increase in collaboration revenue ($482.6 million) from CARVYKTI sales and a 293.6% increase in license revenue ($138.4 million) due to the Novartis License Agreement and Janssen milestones.
• Profitability Improvement: Net loss narrowed significantly from $518.3 million in 2023 to $177.0 million in 2024. This improvement was aided by the $108.5 million unrealized foreign exchange gain and increased revenue.
• Expense Increases: Operating expenses rose across the board:
  • Research and Development (R&D) expenses increased 8.2% to $413.5 million.
  • Selling and Distribution expenses increased 56.6% to $147.5 million, reflecting the expansion of the sales force and second-line indication launch.
  • Administrative expenses increased 28.1% to $136.8 million.
• Liquidity Shift: While total liquidity remained robust at approximately $1.1 billion, the composition shifted. Cash and cash equivalents decreased by $991.0 million, while time deposits increased by $805.6 million, indicating a strategic shift toward longer-term deposits.

Guidance, Outlook, and Risks

Outlook and Guidance:

• The company expects to incur operating losses in the near term as it advances clinical development and expands commercialization.
• Management believes existing cash, cash equivalents, and time deposits ($1.1 billion) will fund operations and capital expenditures into the second quarter of fiscal year 2026.
• Future capital requirements depend on the progress of clinical trials, regulatory approvals, and the commercial success of CARVYKTI.

Key Risks and Contingencies:

• Commercial Dependence: The company is substantially dependent on the commercial success of CARVYKTI. Failure to successfully commercialize this product would materially harm the business.
• Regulatory and Safety: Risks include potential adverse side effects (e.g., secondary hematological malignancies), regulatory investigations, and the need for label updates. The FDA is investigating safety signals related to T-cell malignancies in CAR-T therapies.
• China Operations: Significant risks exist regarding PRC regulations, including the "Negative List" prohibiting foreign investment in human stem cell or gene diagnostic/therapeutic technologies (though the company believes its CAR-T activities are compliant), data privacy laws, and potential restrictions on cross-border data transfer.
• Manufacturing: Scaling manufacturing capacity for cell therapies is complex. The company relies on third-party contract manufacturing organizations (CMOs) and faces risks related to supply chain constraints and quality control.
• Collaboration Risks: The company relies heavily on its collaboration with Janssen Biotech (Johnson & Johnson) for global commercialization outside Greater China and with Novartis for DLL-3 targeting therapies. Termination or underperformance by these partners would be detrimental.

Investor Verification Checklist

• CARVYKTI Sales Trajectory: Verify the growth rate of collaboration revenue and the impact of the expanded label (second-line therapy) on future sales projections.
• Foreign Exchange Impact: Assess the sustainability of the $108.5 million unrealized foreign exchange gain and its impact on future earnings volatility.
• Novartis Agreement Milestones: Monitor the progress of the Legend Phase 1 Trial for LB2102 to determine the timing of revenue recognition for the $100 million upfront payment and potential future milestones.
• China Regulatory Compliance: Confirm the company's ongoing compliance with the PRC "Negative List" and data security regulations, specifically regarding the classification of CAR-T therapies.
• Manufacturing Capacity: Evaluate the status of the company's manufacturing facilities in the US, Belgium, and China, and the reliance on CMOs like Novartis for supply.
• Cash Burn Rate: Review the quarterly cash burn rate to validate the management's assertion that current liquidity is sufficient through Q2 2026.